Advertisement

Topics

AbbVie, Gilead target sick hepatitis C patients in EU

05:23 EDT 1 Aug 2017 | pharmaphorum

Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens. AbbVie’s Maviret (glecaprevir+pibrentasvir) and Gilead’s Vosevi (s...

Original Article: AbbVie, Gilead target sick hepatitis C patients in EU

NEXT ARTICLE

More From BioPortfolio on "AbbVie, Gilead target sick hepatitis C patients in EU"

Quick Search
Advertisement
 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...